Damages in Life Sciences Arbitration
In this chapter published in The Guide to Damages in International Arbitration, Gregory Bell, Andrew Tepperman, and Justin Ho provide a brief overview of...
This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
Dr. Justin Ho is a Principal in the Life Sciences Practice. He is an experienced consultant in legal matters involving intellectual property, antitrust, and other commercial disputes concerning both liability and damages issues.
Dr. Ho has worked on matters involving a range of products, including biologics, small-molecule drugs, and medical devices. He has built substantial expertise in the business and regulatory considerations underlying drug and medical device development that complement his experience in economic analyses. For nearly a decade, he has been advising clients on disputes regarding efforts in drug development (license disputes and contract breach), antitrust matters (market definition and damages in reverse-payment settlements, and product tying), intellectual property disputes (evaluation of commercial success in ANDA litigation, reasonable royalty, and lost profit analyses), pricing (price fixing and welfare analyses), and product labeling matters (including both consumer and pharmaceutical product claims).
Dr. Ho’s doctoral work focused on industrial organization and the economic and strategic evaluation of firm behavior and contracting. His work has been published in the American Economic Review and the Journal of Industrial Economics.